Medicine information PYLERA 140mg / 125mg / 125mg capsules

Product code:
W72178001
Quantity:
120
Indicated for:
Helicobacter pylori eradication with omeprazole and prevention of recurrence of associated peptic ulcer disease
Route of administration:
oral
Substance:
bismuth subcitrate + metronidazole + tetracycline (bismuth compound+nitroimidazole antibacterial+tetracycline antibacterial)
ATC
A02BD08 — Alimentary tract and metabolism | Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) | Combinations for eradication of helicobacter pylori
Bismuth subcitrate + metronidazole + tetracycline is used in adults to eradicate Helicobacter pylori, a bacterium associated with stomach and duodenal ulcers. Bismuth and the two antibiotics act together against the organism. Treatment is combined with omeprazole, which reduces stomach acid and supports ulcer healing.

Take the capsules in divided doses after meals and at bedtime, usually for 10 days, as prescribed. Swallow them whole with a large glass of water and do not lie down immediately afterwards. Do not take them at the same time as dairy products, antacids, iron or zinc supplements. Complete the course and do not double missed doses.

Possible side effects include nausea, diarrhoea, abdominal pain, metallic taste and darkening of stools or the tongue. Bismuth-related colouring is usually harmless, but black stools with weakness or dizziness need assessment. Avoid intense sunlight. Severe diarrhoea, persistent tingling or blistering rashes require prompt medical advice.

Avoid alcohol during treatment and afterwards for the period stated in the leaflet. The combination is contraindicated during pregnancy and breastfeeding and in kidney or liver impairment. Tell the doctor if you take anticoagulants, lithium or retinoids. Breathing difficulty, facial swelling or vomiting blood requires urgent help.

General data about PYLERA 140mg / 125mg / 125mg

Substance:
bismuth subcitrate + metronidazole + tetracycline
Date of latest medicines list:
01-10-2026
Product code:
W72178001
Strength:
140mg / 125mg / 125mg
Pharmaceutical form:
capsules
Quantity:
120
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
SKYEPHARMA PRODUCTION S.A.S. - FRANTA
Holder:
LABORATOIRES JUVISE PHARMACEUTICALS - FRANTA
Number:
16834/2026/01
Shelf life:
3 years

Official documents

Warnings:

Take with food

Take this medicine with food.

Driving impairment

This medicine may affect your ability to drive or use machines.

General warning

Read the package leaflet before use.

Colitis / severe diarrhea

Seek medical advice if severe or persistent diarrhea occurs.

Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Contraindicated in children

Do not give to children for whom it is contraindicated.

Avoid alcohol

Avoid alcohol during treatment.

Avoid milk, calcium, iron, or antacids

Do not take with milk, calcium, iron, magnesium, or antacids if separation is recommended.

Photosensitivity

Avoid excessive exposure to sunlight or UV radiation.

Hepatotoxicity

This medicine may affect the liver.

Major drug interactions

This medicine may have important interactions with other medicines.

Neuropathy / neurotoxicity

This medicine may affect the nerves or nervous system.

Do not split / crush / chew

Do not split, crush, or chew this medicine.

Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

Seizure risk

This medicine may increase the risk of seizures.

Vision disturbances

This medicine may cause vision disturbances.